Rentschler Biopharma and XL-protein demonstrate efficient production of a hyperactive PASylated DNase I with extended half-life
Hyperactive DNase I modified with XL-protein’s PASylation®…
XL-protein announces the Avi-PA(S)™ MAb platform to boost the preclinical and clinical development of therapies using its PASylation® technology
FREISING, GERMANY, July 12, 2021 – XL-protein GmbH, a German…
Akari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting PASylated Nomacopan to Treat Retinal Diseases, Including Age-Related Macular Degeneration (AMD) and Uveitis
NEW YORK and LONDON, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Akari…